News | April 28, 2010

Melanin Injection Protects Against Radiation Therapy Effects

April 28, 2010 - Infusing tiny, melanin-covered nanoparticles into patients may protect bone marrow from the harmful effects of radiation therapy, according to scientists at Albert Einstein College of Medicine of Yeshiva University in New York City.

The study, which is described in the current issue of the International Journal of Radiation Oncology, Biology and Physics, was tested on mouse models. Melanin naturally shields the skin from the damaging effects of sunlight and has been shown to protect against radiation. This technique for shielding normal cells from radiation damage could allow doctors to administer higher doses of radiation to tumors, making the treatment more effective.

Ekaterina Dadachova, Ph.D., associate professor of nuclear medicine and of microbiology and immunology and the Sylvia and Robert S. Olnick faculty scholar in cancer research at Einstein, led the study. Dadachova and her colleagues focused on packaging melanin in particles so small that they would not get trapped by the lungs, liver or spleen. They created melanin nanoparticles by coating tiny (20 nanometers in diameter) silica particles with several layers of melanin pigment that they synthesized in their laboratory.

The researchers found that these particles successfully lodged in bone marrow after being injected into mice. Then, in a series of experiments, they investigated whether their nanoparticles would protect the bone marrow of mice treated with two types of radiation.

One group of mice was injected with nanoparticles and a second group was not. Three hours later, both groups were exposed to whole-body radiation. The levels of white cells and platelets dropped in those receiving melanin nanoparticles before radiation exposure. Ten days after irradiation, platelet levels had fallen by only 10 percent in mice that had received nanoparticles compared with a 60 percent decline in untreated mice. The levels of white blood cells and platelets returned to normal much more quickly than in the control mice.

Clinical trials testing whether melanized nanoparticles might protect cancer patients undergoing radiation therapy could begin in two to three years.

The paper, "Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer," was published in the April 26 online issue of the International Journal of Radiation Oncology, Biology and Physics. Other researchers involved in the study are Ekaterina Revskaya, Ph.D., Peter Chu, B.Sc., Matthew Friedman, Joshua D. Nosanchuk, M.D., Sean Cahill, Ph.D., and Susana Frases, Ph.D., all from Einstein, and Valeria Pazo, M.D., of Jacobi Medical Center.

For more information: www.redjournal.org/article/S0360-3016%2810%2900254-3/abstract

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init